Device Trial Radar · NCT03127722
Study to Assess Outcomes in Women Undergoing Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
990
Actual
Start
May 3, 2017
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- BayerNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 25, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- Female only, from 21 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is designed to assess post-procedural outcomes for women who chose to undergo either hysteroscopic sterilization (Essure®) or laparoscopic tubal sterilization, including: * Pelvic and/or lower abdominal pain * Abnormal uterine bleeding * Surgical intervention (including "insert removal" and hysterectomy) * Allergic, hypersensitivity, or autoimmune-like reactions
Conditions
- Contraception
Interventions
Blood drawProcedure
Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.
ESSURE (BAY1454032)Device
Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
Laparoscopic tubal sterilizationProcedure
Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects Reporting AEs of Chronic Lower Abdominal and/or Pelvic Pain After Insertion of Essure System or After Laparoscopic Tubal SterilizationTime frame: Up to 60 months
- Bleeding: The Proportion of Subjects Reporting AEs of Abnormal Uterine Bleeding (AUB) After Insertion of Essure System Compared to the Proportion of Subjects Reporting AEs of AUB After Laparoscopic Tubal SterilizationTime frame: Up to 60 months
- Proportion of Subjects With Reported Allergic/Hypersensitivity ReactionsTime frame: Up to 60 months
2 more outcomes with a free account
Locations
57 sites in 1 country. Site status is shown where the registry gives one.
New Horizons Women's Care
Chandler, Arizona
Precision Trials, AZ, LLC
Phoenix, Arizona
Visions Clinical Research - Tucson
Tucson, Arizona
54 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.